Beijing National Laboratory for Molecular Sciences (BNLMS), Key Laboratory of Colloid and Interface Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing, PR China.
Langmuir. 2011 Feb 15;27(4):1499-504. doi: 10.1021/la103696z. Epub 2010 Nov 10.
Insulin/alginate (ALG) microcapsules for controllable release and side effect reduction of a glucocorticoid have been fabricated via the layer-by-layer (LbL) assembly technique. Insulin and ALG are deposited alternately onto hydrocortisone (HC) crystals to form a core-shell structure. This insulin/ALG microcapsule can prolong the release of HC under physical conditions and control the HC release rate by adjusting the number of insulin/ALG bilayers adsorbed onto HC crystals. The release of insulin from the capsule wall exhibits a little lag, compared with that of the HC. It is a great advantage for this system because hyperglycemia caused by HC usually arises a few hours after its administration, which could be inhibited by the delayed release of insulin from the shell of the microcapsule. This synergy effect might enable a new way of using one carrier to deliver two kinds of drugs and reduce their side effects at the same time.
通过层层（LbL）组装技术制备了用于控制糖皮质激素释放和减少副作用的胰岛素/海藻酸钠（ALG）微胶囊。将胰岛素和 ALG 交替沉积在氢化可的松（HC）晶体上，形成核壳结构。这种胰岛素/ALG 微胶囊可以在物理条件下延长 HC 的释放，并通过调节吸附在 HC 晶体上的胰岛素/ALG 双层的数量来控制 HC 的释放速率。与 HC 相比，胰岛素从胶囊壁的释放表现出稍滞后。对于该系统来说，这是一个很大的优势，因为 HC 给药后几小时通常会引起高血糖，而这可以通过微胶囊壳中胰岛素的延迟释放来抑制。这种协同作用可能为使用一种载体同时输送两种药物并同时减少其副作用提供一种新方法。
